BofA Global Research cut its target price of Paytm's parent company, One97 Communications Ltd., on Friday, citing near-term challenges following a change in strategy and a reduced number of loans.
The brokerage cut the target price on the stock to Rs 905 from Rs 1,165 earlier, implying a 32.15% upside from its market price as of 12:06 p.m. It has reiterated its 'buy' rating for the stock.
However, its structural story remains intact on the back of better take rates and cost control. The stock's risk-reward ratio is also favourable, BofA said in a note.
"Paytm stock price is down 28% in the last three months vs. Nifty up 10%, mainly after its change in strategy of de-focusing on low-margin BNPL loans," it said.
BofA highlighted several factors that the market is missing, including a shift away from the buy-now, pay-later method that would improve the take rate to 3.8–4% in the coming quarters from 3.3% in the second quarter. It also cited the tie-up with Axis Bank in the personal-loan space going live in the fourth quarter.
Levers like cost control and embedded insurance uptake would result in 6% and 11% Ebitda margins in the current and next financial years, respectively. Other catalysts for the stock include more lending partner onboarding and consensus upgrades, led by cost control and take-rate uptake, according to BofA.
On the NSE, Paytm's stock rose 1.98% during the day to Rs 681.95 apiece, the highest since Dec. 7. It was trading 1.9% higher at Rs 681.40 apiece, compared to a 0.32% advance in the benchmark Nifty 50 at 10:30 a.m.
The share price has risen 25.11% in the last 12 months. The relative strength index was at 45.78.
Ten out of 15 analysts tracking the company have a 'buy' rating on the stock and five recommend a 'hold', according to Bloomberg data. The average of 12-month analyst price targets implies a potential upside of 44.4%.
RECOMMENDED FOR YOU

Market Experts' LIVE Stock Recommendations: Buy, Sell Or Hold Today?


Torrent Pharma Target Price Hiked By BofA On Likely Margin Synergies After JB Deal

Dr. Reddy's Laboratories' Target Price Hiked By BofA As New Launches To Boost Revenue


Indian Bank, Paytm — Check Aditya Agarwala's Top Picks
